Sign up to save your podcasts
Or
Share : Ruth O'Regan, MD
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
: Ruth O'Regan, MD
Biologic Rationale, Development History, and Practical Dosing and Administration: CDK 4/6 Inhibitor Therapy for ER+ Metastatic Breast Cancer - Advancing Nursing Care to Improve Patient Outcomes
View all episodes
By ImedexBiologic Rationale, Development History, and Practical Dosing and Administration: CDK 4/6 Inhibitor Therapy for ER+ Metastatic Breast Cancer - Advancing Nursing Care to Improve Patient Outcomes